These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 27438687)
1. Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder. Smagula SF; Wallace ML; Anderson SJ; Karp JF; Lenze EJ; Mulsant BH; Butters MA; Blumberger DM; Diniz BS; Lotrich FE; Dew MA; Reynolds CF J Psychiatr Res; 2016 Oct; 81():112-8. PubMed ID: 27438687 [TBL] [Abstract][Full Text] [Related]
2. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial. Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689 [TBL] [Abstract][Full Text] [Related]
3. Impact of Prior Treatment on Remission of Late-Life Depression with Venlafaxine and Subsequent Aripiprazole or Placebo Augmentation. Hsu JH; Mulsant BH; Lenze EJ; Karp JF; Lavretsky H; Roose SP; Reynolds CF; Blumberger DM Am J Geriatr Psychiatry; 2016 Oct; 24(10):918-22. PubMed ID: 27538352 [TBL] [Abstract][Full Text] [Related]
4. Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole. Oughli H; Lenze EJ; Locke AE; Yingling MD; Zhong Y; Miller JP; Reynolds CF; Mulsant BH; Newcomer JW; Peterson TR; Müller DJ; Nicol GE J Psychiatr Res; 2019 Jul; 114():67-74. PubMed ID: 31039482 [TBL] [Abstract][Full Text] [Related]
5. Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy. Casey DE; Laubmeier KK; Eudicone JM; Marcus R; Berman RM; Rahman Z; Sheehan J Int J Clin Pract; 2014 Nov; 68(11):1301-8. PubMed ID: 25196314 [TBL] [Abstract][Full Text] [Related]
6. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. Lin CH; Lin SH; Jang FL J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699 [TBL] [Abstract][Full Text] [Related]
7. Predicting Remission in Late-Life Major Depression: A Clinical Algorithm Based Upon Past Treatment History. Buchalter ELF; Oughli HA; Lenze EJ; Dixon D; Miller JP; Blumberger DM; Karp JF; Reynolds CF; Mulsant BH J Clin Psychiatry; 2019 Dec; 80(6):. PubMed ID: 31846575 [TBL] [Abstract][Full Text] [Related]
8. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475 [TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725 [TBL] [Abstract][Full Text] [Related]
10. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder. Weisler RH; Khan A; Trivedi MH; Yang H; Eudicone JM; Pikalov A; Tran QV; Berman RM; Carlson BX J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039 [TBL] [Abstract][Full Text] [Related]
11. General Predictors and Moderators of Depression Remission: A VAST-D Report. Zisook S; Johnson GR; Tal I; Hicks P; Chen P; Davis L; Thase M; Zhao Y; Vertrees J; Mohamed S Am J Psychiatry; 2019 May; 176(5):348-357. PubMed ID: 30947531 [TBL] [Abstract][Full Text] [Related]
12. Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder. Wisniewski SR; Chen CC; Kim E; Kan HJ; Guo Z; Carlson BX; Tran QV; Pikalov A Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):965-72. PubMed ID: 19662630 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. Mischoulon D; Witte J; Levy M; Papakostas GI; Pet LR; Hsieh WH; Pencina MJ; Ward S; Pollack MH; Fava M J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of aripiprazole as adjunctive therapy in major depressive disorder with somatic symptoms: A randomized, double-blind, placebo-controlled trial with clinical and electroencephalography evidence. Kim HJ; Han DH; Choi KT; Hwang HC; Min KJ; Kim SM J Psychopharmacol; 2023 Mar; 37(3):289-302. PubMed ID: 36239033 [TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder. Boulton DW; Balch AH; Royzman K; Patel CG; Berman RM; Mallikaarjun S; Reeves RA J Psychopharmacol; 2010 Apr; 24(4):537-46. PubMed ID: 18832427 [TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lenze EJ; Mulsant BH; Blumberger DM; Karp JF; Newcomer JW; Anderson SJ; Dew MA; Butters MA; Stack JA; Begley AE; Reynolds CF Lancet; 2015 Dec; 386(10011):2404-12. PubMed ID: 26423182 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Nelson JC; Thase ME; Bellocchio EE; Rollin LM; Eudicone JM; McQuade RD; Marcus RN; Berman RM; Baker RA Int Clin Psychopharmacol; 2012 May; 27(3):125-33. PubMed ID: 22466058 [TBL] [Abstract][Full Text] [Related]
19. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. Mohamed S; Johnson GR; Chen P; Hicks PB; Davis LL; Yoon J; Gleason TC; Vertrees JE; Weingart K; Tal I; Scrymgeour A; Lawrence DD; Planeta B; Thase ME; Huang GD; Zisook S; ; Rao SD; Pilkinton PD; Wilcox JA; Iranmanesh A; Sapra M; Jurjus G; Michalets JP; Aslam M; Beresford T; Anderson KD; Fernando R; Ramaswamy S; Kasckow J; Westermeyer J; Yoon G; D'Souza DC; Larson G; Anderson WG; Klatt M; Fareed A; Thompson SI; Carrera CJ; Williams SS; Juergens TM; Albers LJ; Nasdahl CS; Villarreal G; Winston JL; Nogues CA; Connolly KR; Tapp A; Jones KA; Khatkhate G; Marri S; Suppes T; LaMotte J; Hurley R; Mayeda AR; Niculescu AB; Fischer BA; Loreck DJ; Rosenlicht N; Lieske S; Finkel MS; Little JT JAMA; 2017 Jul; 318(2):132-145. PubMed ID: 28697253 [TBL] [Abstract][Full Text] [Related]
20. Association between lean muscle mass and treatment-resistant late-life depression in the IRL-GRey randomized controlled trial. Ainsworth NJ; Brender R; Gotlieb N; Zhao H; Blumberger DM; Karp JF; Lenze EJ; Nicol GE; Reynolds CF; Wang W; Mulsant BH Int Psychogeriatr; 2023 Dec; 35(12):707-716. PubMed ID: 36594430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]